Market Place
Sourcing Support
Lineage Cell Therapeutics Announces $66M Direct Offering
20 Nov 2024 //
BUSINESSWIRE
Lineage Cell Therapeutics Reports Q3 2024 Financial Results
14 Nov 2024 //
BUSINESSWIRE
Lineage Cell Therapeutics to Report Q3 2024 Results on Nov 14
07 Nov 2024 //
BUSINESSWIRE
OpRegen® Results To Be Featured At ISSCR 2024 Symposium
25 Sep 2024 //
BUSINESSWIRE
Lineage Cell To Present At H.C. Wainwright Ophthalmology Conference
13 Aug 2024 //
BUSINESSWIRE
Lineage Cell Therapeutics Reports Q2 2024 Results And Business Update
08 Aug 2024 //
BUSINESSWIRE
Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index
02 Jul 2024 //
BUSINESSWIRE
Lineage to Present at 2024 BIO International Convention
30 May 2024 //
BUSINESSWIRE
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
21 May 2024 //
BUSINESSWIRE
OpRegen® Phase 1/2a study shows promising 24-month visual results
06 May 2024 //
BUSINESSWIRE
Lineage To Report Q1 2024 Results, Business Update On May 9
02 May 2024 //
BUSINESSWIRE
Lineage Receives Grant From California`s CIRM
30 Apr 2024 //
BUSINESSWIRE
Lineage Cell Reports Fourth Quarter and Full Year 2023 Financial Results
07 Mar 2024 //
BUSINESSWIRE
Lineage Cell to Report Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
BUSINESSWIRE
Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant
13 Feb 2024 //
BUSINESSWIRE
Lineage Announces Submission of OPC1 New Drug Amendment for Spinal Cord Injury
18 Dec 2023 //
BUSINESSWIRE
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
BUSINESSWIRE
Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results
01 Nov 2023 //
BUSINESSWIRE
Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference
19 Sep 2023 //
BUSINESSWIRE
Lineage to Present at 2023 International Spinal Research Trust Network Meeting
11 Sep 2023 //
BUSINESSWIRE
Lineage Announces Initiation of Activities for Hypoimmune Pluripotent Cell Line
06 Sep 2023 //
BUSINESSWIRE
Lineage to Present at Baird 2023 Global & H.C. Wainwright & Co. 25th Conference
29 Aug 2023 //
BUSINESSWIRE
Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
BUSINESSWIRE
Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results
03 Aug 2023 //
BUSINESSWIRE
Lineage Cell and Cancer Research UK Report Phase 1 Study Results With VAC2
24 Jul 2023 //
BUSINESSWIRE
Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index
22 May 2023 //
BUSINESSWIRE
Retrospective Analysis of Data Evaluating Safety & Efficacy of REBYOTA™
04 May 2023 //
BUSINESSWIRE
Lineage Cell to Report 1Q 2023 FYR & Business Update on May 11, 2023
04 May 2023 //
BUSINESSWIRE
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen
26 Apr 2023 //
BUSINESSWIRE
Lineage to Present at 2023 AAPS National Biotechnology Conference
18 Apr 2023 //
BUSINESSWIRE
RG6501 Phase 1/2a Results to Be Presented at 2023 Retinal Cell Summit
20 Mar 2023 //
BUSINESSWIRE
Lineage Cell Reports Fourth Quarter and Full Year 2022 Financial Results
09 Mar 2023 //
BUSINESSWIRE
Lineage Cell to Report Fourth Quarter and Full Year 2022 Financial Results
02 Mar 2023 //
BUSINESSWIRE
Eterna Therapeutics Enters Into Agreement with Lineage Cell Therapeutics
22 Feb 2023 //
GLOBENEWSWIRE
Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®)
28 Nov 2022 //
BUSINESSWIRE
Lineage Cell Therapeutics Reports 3Q 2022 Financial Results
10 Nov 2022 //
BUSINESSWIRE
Lineage Cell Therapeutics Appoints Jill Howe as CFO
31 Oct 2022 //
BUSINESSWIRE
Lineage Cell Therapeutics, Asterias Investors Propose Settlement
29 Oct 2022 //
BLOOMBERGLAW
Lineage opens new California R&D facility and expands Israel manufacturing site
13 Oct 2022 //
ENDPTS
Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
BUSINESSWIRE
Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results
04 Aug 2022 //
BUSINESSWIRE
Lineage, Advanced BioMatrix Extend Collaboration for Drug Delivery Technology
02 Jun 2022 //
BUSINESSWIRE
Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results
12 May 2022 //
BUSINESSWIRE
Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results
05 May 2022 //
BUSINESSWIRE
RG6501 PI/IIa Results Support the Potential for OpRegen in Geographic Atrophy
03 May 2022 //
BUSINESSWIRE
Lineage Announces a 5th Cell Therapy Pro llogeneic Photoreceptor Transplants
25 Apr 2022 //
BUSINESSWIRE
Lineage and Cancer Research UK Completes Enrollment in PI Study of VAC2
13 Apr 2022 //
BUSINESSWIRE
RG6501 Full Phase 1/2a Results to Be Featured at 2022 ARVO
14 Mar 2022 //
BUSINESSWIRE
Lineage Cell Tx Reports Q4 and Full Year 2021 Financial Results
10 Mar 2022 //
BUSINESSWIRE
Roche builds Genentech`s ophthalmology program with $670M deal
21 Dec 2021 //
FIERCEBIOTECH
Lineage Reports Q3 2021 Financial Results, Highlights Progress
10 Nov 2021 //
BUSINESSWIRE
OpRegen Provides Improvements in Patients With Dry AMD With GA: Trial Data
15 Sep 2021 //
BUSINESSWIRE
Opregen Data Update To Be Featured at 54th Annual Retina Society Meeting
13 Sep 2021 //
BUSINESSWIRE
Lineage Announces Appointment of General Counsel
01 Sep 2021 //
BUSINESSWIRE
Lineage Reports Second Quarter 2021 Financial Results and Highlights
12 Aug 2021 //
BUSINESSWIRE
Lineage to Present at the H.C. Wainwright Ophthalmology Conference
10 Aug 2021 //
BUSINESSWIRE
OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting
13 Jul 2021 //
BUSINESSWIRE
Lineage Cell Therapeutics Joins Russell 3000® and Russell Microcap® Indexes
28 Jun 2021 //
BUSINESSWIRE
Lineage Cell to Present at Raymond James 2021 Human Health Innovation Conference
15 Jun 2021 //
BUSINESSWIRE
Lineage Cell Set to Join Russell 3000® Index and Russell Microcap® Index
09 Jun 2021 //
BUSINESSWIRE
